Marlex Acetaminophen Tablets Recalled for Manufacturing Practice Deviations
Marlex Pharmaceuticals is recalling 28,387 bottles of Acetaminophen Tablets, 500 mg, because the lot was not manufactured under current good manufacturing practices.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II due to CGMP deviations. Per the rubric, this falls under 'Moderate' as it involves a manufacturing violation without reported illnesses or specific high-risk pathogens.
Plain-English summary
Marlex Pharmaceuticals, Inc. is recalling 28,387 bottles of Acetaminophen Tablets, 500 mg, 100-count bottles. The product is identified by Lot # 3213, Exp 12/13, NDC 10135-152-01, and UPC 3 10135 15201 8. The recall is being conducted nationwide.
The recall was initiated because the specific lot of acetaminophen tablets was not manufactured under current good manufacturing practices (CGMP), as noted by a recent inspection of the manufacturing firm. This is an FDA Class II recall, which indicates a violation of CGMP that may cause temporary or medically reversible adverse health consequences.
Consumers who have this product should stop using it and return it to the place of purchase for a refund or contact Marlex Pharmaceuticals, Inc. for further instructions.
The recalled product
- Product
- Acetaminophen Tablets, 500 mg, 100-count bottles, Distributed by: Marlex Pharmaceuticals, Inc., New Castle, DE 19720, List No. 152, NDC 10135-152-01, UPC 3 10135 15201 8.
- Manufacturer
- Marlex Pharmaceuticals, Inc.
- Category
- Drug — Tablets
- Hazard
- Affected units
- 28,387
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 3213
- Exp 12/13
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Marlex Pharmaceuticals, Inc.
See all →- SevereDigoxin Tablets Nationwide Recall: Bottles Mislabeled with Incorrect Dosages
FDA (Drugs) · 2023-09-13
- HighDigoxin Tablets Recalled Due to Reversed Dosage Labeling
FDA (Drugs) · 2023-09-13
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19